

PB 105 of 2025

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 9)

National Health Act 1953

I, REBECCA RICHARDSON, Assistant Secretary, PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 84AAA(2) of the *National Health Act 1953*.

Dated 29 September 2025

**REBECCA RICHARDSON**
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division

Contents

1. Name 1

2. Commencement 1

3. Authority 1

4. Schedules 1

Schedule 1—Amendments 2

*National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)* 2

1. Name

(1) This instrument is the *National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 9)*.

(2) This instrument may also be cited as PB 105 of 2025.

2. Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

|  |
| --- |
| **Commencement information** |
| **Column 1** | **Column 2** | **Column 3** |
| **Provisions** | **Commencement** | **Date/Details** |
| 1. The whole of this instrument | 1 October 2025 | 1 October 2025 |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3. Authority

This instrument is made under subsection 84AAA(2) of the *National Health Act 1953*.

4. Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

*National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)*

[1] Schedule 1, after entry for Dabigatran etexilate in the form Capsule 150 mg (as mesilate)

insert:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Dabrafenib | Capsule 50 mg (as mesilate) | 20 | 120 | 5 |  |
|  | Capsule 75 mg (as mesilate) | 20 | 120 | 5 |  |

[2] Schedule 1, after entry for Esomeprazole and clarithromycin and amoxicillin in the form Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate)

insert:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estetrol with drospirenone | Pack containing 24 tablets estetrol 14.2 mg (as monohydrate) with drospirenone 3 mg and 4 inert tablets | 20 | 3 | 3 |  |

[3] Schedule 1, entry for Glyceryl trinitrate

omit:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Transdermal patch 36 mg | 20 | 30 | 5 |  |

[4] Schedule 1, omit entry for Ketoprofen

[5] Schedule 1, after entry for Lisinopril in the form Tablet 20 mg

insert:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Lumasiran | Solution for subcutaneous injection 94.5 mg (as sodium) in 0.5 mL | 20 | 5 | 1 |  |
|  |  | 20 | 5 | 2 |  |

[6] Schedule 1, entry for Ramipril with felodipine

omit:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Tablet 2.5  mg‑2.5 mg (modified release) | 20 | 30 | 5 |  |

[7] Schedule 1, after entry for Topiramate in the form Tablet 200 mg

insert:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Trametinib | Tablet 2 mg | 20 | 30 | 5 |  |
|  | Tablet 500 micrograms | 20 | 90 | 5 |  |

[8] Schedule 2, after entry for Ezetimibe with simvastatin in the form Tablet 10 mg‑80 mg

insert:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Famotidine | Tablet 20 mg | 50 | 120 | 5 |  |
|  | Tablet 40 mg | 50 | 60 | 5 |  |

[9] Schedule 2, entry for Glyceryl trinitrate

omit:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Transdermal patch 36 mg | 50 | 60 | 5 |  |

[10] Schedule 2, entry for Ramipril with felodipine

omit:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Tablet 2.5 mg‑2.5 mg (modified release) | 50 | 60 | 5 |  |

[11] Schedule 2, after entry for Ticagrelor

insert:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Timolol | Eye drops (gellan gum solution) 5 mg (as maleate) per mL, 2.5 mL | 50 | 2 | 5 |  |
|  | Eye drops 5 mg (as maleate) per mL, 5 mL | 50 | 2 | 5 |  |